company background image
5001

Procter & Gamble HealthBSE:500126 Stock Report

Market Cap

₹90.1b

7D

-3.3%

1Y

6.4%

Updated

25 Oct, 2021

Data

Company Financials
500126 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends2/6

500126 Overview

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India.

Procter & Gamble Health Competitors

Abbott India

BSE:500488

₹430.3b

GlaxoSmithKline Pharmaceuticals

BSE:500660

₹248.2b

Pfizer

BSE:500680

₹235.9b

Sanofi India

BSE:500674

₹192.7b

Price History & Performance

Summary of all time highs, changes and price drops for Procter & Gamble Health
Historical stock prices
Current Share Price₹5,382.70
52 Week High₹5,000.00
52 Week Low₹7,499.95
Beta0.29
1 Month Change0.021%
3 Month Change-0.58%
1 Year Change6.38%
3 Year Change83.38%
5 Year Change538.44%
Change since IPO130,865.94%

Recent News & Updates

Shareholder Returns

500126IN PharmaceuticalsIN Market
7D-3.3%-4.7%-3.1%
1Y6.4%18.5%61.0%

Return vs Industry: 500126 underperformed the Indian Pharmaceuticals industry which returned 18.5% over the past year.

Return vs Market: 500126 underperformed the Indian Market which returned 61% over the past year.

Price Volatility

Is 500126's price volatile compared to industry and market?
500126 volatility
500126 Beta0.29
Industry Beta0.60
Market Beta1

Stable Share Price: 500126 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: 500126's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19671,362Milind Thattehttps://www.pghealthindia.com

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas brands.

Procter & Gamble Health Fundamentals Summary

How do Procter & Gamble Health's earnings and revenue compare to its market cap?
500126 fundamental statistics
Market Cap₹90.09b
Earnings (TTM)₹1.77b
Revenue (TTM)₹10.09b

50.5x

P/E Ratio

8.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
500126 income statement (TTM)
Revenue₹10.09b
Cost of Revenue₹3.27b
Gross Profit₹6.82b
Expenses₹5.05b
Earnings₹1.77b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 09, 2021

Earnings per share (EPS)106.51
Gross Margin67.62%
Net Profit Margin17.53%
Debt/Equity Ratio0%

How did 500126 perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

38%

Payout Ratio

Does 500126 pay a reliable dividends?

See 500126 dividend history and benchmarks
When do you need to buy 500126 by to receive an upcoming dividend?
Procter & Gamble Health dividend dates
Ex Dividend DateNov 02 2021
Dividend Pay DateDec 08 2021
Days until Ex dividend7 days
Days until Dividend pay date43 days

Does 500126 pay a reliable dividends?

See 500126 dividend history and benchmarks

Valuation

Is Procter & Gamble Health undervalued compared to its fair value and its price relative to the market?

6.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 500126 (₹5382.7) is trading below our estimate of fair value (₹5726.46)

Significantly Below Fair Value: 500126 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 500126 is poor value based on its PE Ratio (50.5x) compared to the Indian Pharmaceuticals industry average (24.3x).

PE vs Market: 500126 is poor value based on its PE Ratio (50.5x) compared to the Indian market (21.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500126's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 500126 is overvalued based on its PB Ratio (12.7x) compared to the IN Pharmaceuticals industry average (3x).


Future Growth

How is Procter & Gamble Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Procter & Gamble Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Procter & Gamble Health performed over the past 5 years?

23.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500126 has high quality earnings.

Growing Profit Margin: 500126's current net profit margins (17.5%) are lower than last year (18.7%).


Past Earnings Growth Analysis

Earnings Trend: 500126's earnings have grown significantly by 23.1% per year over the past 5 years.

Accelerating Growth: 500126's earnings growth over the past year (6.6%) is below its 5-year average (23.1% per year).

Earnings vs Industry: 500126 earnings growth over the past year (6.6%) underperformed the Pharmaceuticals industry 35.7%.


Return on Equity

High ROE: 500126's Return on Equity (25.1%) is considered high.


Financial Health

How is Procter & Gamble Health's financial position?


Financial Position Analysis

Short Term Liabilities: 500126's short term assets (₹7.3B) exceed its short term liabilities (₹2.4B).

Long Term Liabilities: 500126's short term assets (₹7.3B) exceed its long term liabilities (₹434.8M).


Debt to Equity History and Analysis

Debt Level: 500126 is debt free.

Reducing Debt: 500126 had no debt 5 years ago.

Debt Coverage: 500126 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 500126 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Procter & Gamble Health current dividend yield, its reliability and sustainability?

0.74%

Current Dividend Yield


Upcoming Dividend Payment

TodayOct 25 2021Ex Dividend DateNov 02 2021Dividend Pay DateDec 08 202136 days from Ex DividendBuy in the next 7 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 500126's dividend (0.74%) is higher than the bottom 25% of dividend payers in the Indian market (0.34%).

High Dividend: 500126's dividend (0.74%) is low compared to the top 25% of dividend payers in the Indian market (1.41%).


Stability and Growth of Payments

Stable Dividend: 500126's dividend payments have been volatile in the past 10 years.

Growing Dividend: 500126's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (37.6%), 500126's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Milind Thatte (52 yo)

3.5yrs

Tenure

₹32,345,000

Compensation

Mr. Milind Vasant Thatte, M.Pharm.Sci., M.B.A., has been Managing Director and Executive Director of Procter & Gamble Health Limited (formerly known as Merck Limited) since April 1, 2018. Mr. Thatte had a...


CEO Compensation Analysis

Compensation vs Market: Milind's total compensation ($USD431.44K) is about average for companies of similar size in the Indian market ($USD425.15K).

Compensation vs Earnings: Milind's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 500126's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: 500126's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Procter & Gamble Health Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Procter & Gamble Health Limited
  • Ticker: 500126
  • Exchange: BSE
  • Founded: 1967
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹90.093b
  • Shares outstanding: 16.60m
  • Website: https://www.pghealthindia.com

Number of Employees


Location

  • Procter & Gamble Health Limited
  • Godrej One
  • 8th Floor, Pirojshanagar
  • Mumbai
  • Maharashtra
  • 400079
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 12:01
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.